Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer

201278 citationsJournal Article

Authors

Mari Nakabayashi · Spanish Oncology Genitourinary Group

Lilian Werner · Dana-Farber Cancer Institute

Kevin D. Courtney · Spanish Oncology Genitourinary Group

Geoffrey Buckle · Spanish Oncology Genitourinary Group

William Oh · Icahn School of Medicine at Mount Sinai

Glen J. Bubley · Beth Israel Deaconess Medical Center

Julia H. Hayes

Abstract

• The combination of RAD001 and bicalutamide in men with CRPC was well tolerated but had low activity and failed to achieve the primary endpoint of improved response compared to the results previously achieved for bicalutamide alone in this population.

Topics & Keywords

Prostate Cancer Treatment and Research PI3K/AKT/mTOR signaling in cancer Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Urology

Volume 110, Issue 11, pp. 1729-1735

DOI: 10.1111/j.1464-410x.2012.11456.x

Field-Weighted Citation Impact: 8.10